Three patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2040. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Dec 2040
Next term end
2
Patent families
When these terms end
Each bar runs from grant to computed term end. 2023 to 2041.
US 12,121,585
Dendrimer Compositions and Methods for Drug Delivery to the Eye
no later than Dec 4, 2040
20272031203520392041
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
10 pending applications: term is not computable until grant.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Dec 2040 · High confidence
Also notable
Ends Oct 2041 · High confidence
Dendrimer Compositions and Methods for Drug Delivery to the Eye
US 11,612,660
Granted 2023. Computed term ends 2040.
Methods of Treating Severe Inflammation
US 11,931,418
Granted 2024. Too new for citation comparison; protection runs to 2041.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Sep 19, 2027The maintenance fee for Methods of Treating Severe Inflammation (US 11,931,418) comes due Sep 19, 2027. Unpaid by Mar 20, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Dendrimer Compositions and Methods for Drug Delivery to the Eye | 2 in force | to Dec 2040 |
| Methods of Treating Severe Inflammation | 1 in force | to Oct 2041 |
Patents held now
Soonest term end first.
Showing 1 to 3 of 3
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,612,660 | Dendrimer Compositions and Methods for Drug Delivery to the Eye In force · High confidence | In force | High confidence | |
| US 12,121,585 | Dendrimer Compositions and Methods for Drug Delivery to the Eye In force · Medium confidence | In force | Medium confidence | |
| US 11,931,418 | Methods of Treating Severe Inflammation In force · High confidence | In force | High confidence |
Also on record, not counted in the 3: 10 applications pending · 1 application abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed